Progress Now: Clinical Trials and Recent Drug Approvals
By MDA Staff | Wednesday, November 18, 2026
Amyotrophic lateral sclerosis (ALS)
Phase 2b Clinical Trial: Results
Neurosense Therapeutics released positive results from the phase 2b PARADIGM study of PrimeC, an experimental oral ALS treatment. In the trial, PrimeC significantly reduced levels of TDP-43, a protein that abnormally accumulates in 97% of ALS cases.
Overview
In many ALS cases, TDP-43 protein forms abnormal clumps inside nerve cells. This is believed to contribute to nerve cell death and help drive disease progression. PrimeC is designed to simultaneously target several key mechanisms of ALS to potentially slow the progression of ALS. PrimeC is administered orally (by mouth).
Key points
- The phase 2b trial included 68 adults with ALS.
- It was a randomized, double-blind, placebo-controlled trial.
- PrimeC produced a statistically significant reduction in TDP-43 compared to a placebo after six months. The effect was larger after 18 months.
- It also showed a statistically significant slowing of signs of functional decline.
- Neurosense is planning a global phase 3 clinical trial.
Learn more
Visit neurosense-tx.com/primec.
Becker muscular dystrophy (BMD) & Duchenne muscular dystrophy (DMD)
Observational Study: Enrolling
Researchers at Carle Foundation Hospital in Urbana, Illinois, are seeking people living with BMD or DMD to participate in an observational study using Diffusion Tensor MRI to examine muscle function and structure. The study aims to better understand why muscles in BMD and DMD may be more prone to damage.
Inclusion criteria include:
- BMD or DMD diagnosis
- Between 8 and 50 years old
- Able to flex toes toward shins
- Able to lie still in an MRI scanner for 75 minutes
Overview
This is an observational study, so no drug or treatment will be tested. Participants will undergo noninvasive MRI imaging of the lower leg muscles and assessments to measure muscle strength.
Timeframe
One online meeting and one four-hour session at the research site
Contact
Study coordinator, Muscle.MRI@carle.com
Dermatomyositis
Treatment News: Drug Approval
In August, the US Food and Drug Administration (FDA) approved brepocitinib (LISRAYA™) to treat adults living with dermatomyositis.
Overview
LISRAYA is the first targeted therapy specifically approved to treat dermatomyositis, an autoimmune disease that causes painful skin rashes and progressive muscle weakness. The disease can significantly affect mobility, swallowing, and breathing, and may also involve the lungs, heart, and gastrointestinal system. Until now, treatment has largely relied on corticosteroids, like prednisone, and other immunosuppressive therapies.
LISRAYA is designed to block a key pathway in the body’s immune and inflammatory responses, which helps reduce the harmful inflammation that damages the muscles and skin in dermatomyositis. It is a pill taken orally (by mouth) once a day.
Learn more
Visit lisraya.com.
Facioscapulohumeral muscular dystrophy (FSHD)
Phase 2 Clinical Trial: Enrolling
Apitegromab, recently approved as a muscle-targeted therapy for spinal muscular atrophy (SMA) (see page 18), is being tested for FSHD in the FORGE trial.
Inclusion criteria include:
- Genetic diagnosis of FSHD
- Between 18 and 60 years old
Overview
FSHD is a muscular dystrophy that causes weakness mainly in muscles of the face, shoulders, and upper arms. Apitegromab is an antibody-based medication designed to block myostatin, a protein that normally helps prevent excessive muscle growth. By targeting myostatin, researchers aim to improve muscle strength in people with FSHD.
The FORGE trial builds on the clinically validated mechanism of apitegromab from the phase 3 clinical study of patients with SMA.
It is a randomized, double-blind, placebo- controlled trial, meaning participants will be randomly assigned to receive an IV infusion (a tube into the vein) of apitegromab or a placebo (inactive substance) every four weeks.
Timeframe
1 year
Location
Austin, Texas
Learn more
Visit ClinicalTrials.gov and enter NCT07435129 in the “Other terms” search box.
Contact
Scholar Rock, Inc., Clinical Trials Administration, 857-259-3860, MedicalInformation@ScholarRock.com
Myasthenia gravis (MG)
Phase 2a Clinical Trial: Enrolling
This trial is evaluating whether adding the experimental therapy empasiprubart to efgartigimod alfa-fcab (Vyvgart) can improve symptoms in people with generalized myasthenia gravis (gMG) who are acetylcholine receptor (AChR) antibody-positive.
Inclusion criteria include:
- Confirmed diagnosis of AChR
- antibody-positive gMG
- Age 18 years or older
Overview
Vyvgart was approved in 2021 by the US Food and Drug Administration (FDA) for adults with AChR antibody-positive gMG, the most common type of gMG. This therapy lowers levels of harmful antibodies. Empasiprubart is an experimental therapy designed to target excessive activation of the complement system, which drives the body’s immune response. This combination aims to improve control of gMG symptoms for people whose symptoms are only partially controlled by Vyvgart alone.
At the start of the trial, participants will only receive Vyvgart. Those who have a partial response will then receive both Vyvgart and empasiprubart. Participants who respond to Vyvgart alone will continue treatment with Vyvgart. Both drugs are administered via IV infusion (a tube into the vein).
Timeframe
54 weeks
Location
33 global sites, including 14 sites in the US
Learn more
Visit ClinicalTrials.gov and enter NCT07294170 in the “Other terms” search box.
Contact
Sabine Coppieters, MD, 857-350-4834, ClinicalTrials@argenx.com
Pompe disease
Phase 3 Clinical Trial: Results
Sanofi released positive results from the phase 3 Baby-COMET study of avalglucosidase alfa (Nexviazyme) in infants up to 12 months old. The trial demonstrated that this enzyme replacement therapy (ERT) may help babies with infantile-onset Pompe disease (IOPD) live longer without breathing assistance.
Overview
Nexviazyme, a next-generation ERT, was approved in 2021 by the US Food and Drug Administration (FDA) to treat late-onset Pompe disease (LOPD) in people ages 1 year and older. It is designed to improve uptake of the essential alpha-glucosidase (GAA) enzyme. This may help clear away the excess glycogen that builds up in muscle cells in people with Pompe, damaging skeletal and cardiac muscles. IOPD, the most aggressive form of Pompe, can cause severe and potentially fatal complications affecting the heart, movement, and breathing in the first months of life.
Key points
- This was a multicenter, open-label study.
- 17 participants received Nexviazyme via IV infusion (a tube into the vein) every other week.
- Positive results include the proportion of participants who survived without using breathing machines after one year of treatment, as well as encouraging signs of heart function and motor skills.
- Sanofi plans to use these results to apply for FDA approval to expand Nexviazyme’s label to include patients with IOPD.
Learn more
Visit ClinicalTrials.gov and enter NCT04910776 in the “Other terms” search box.
Spinal muscular atrophy (SMA)
Treatment News: Drug Approval
In September, the US Food and Drug Administration (FDA) approved Scholar Rock’s apitegromab-mstn (Isembyld) to treat SMA in children and adults (ages 2 years and older) who are currently receiving a survival motor neuron 2 (SMN2)-targeted treatment.
Overview
Isembyld is the first muscle-targeted therapy for SMA that works with existing treatments to address muscle loss. In a phase 3 study, participants who received Isembyld experienced a significant improvement in motor function after one year of treatment, while those on an SMN2-targeted treatment alone lost motor function. FDA-approved SMN2-targeted treatments for SMA include nusinersen (Spinraza) and risdiplam (Evrysdi).
Isembyld is an antibody that recognizes and binds to inactive forms of myostatin, a protein that normally prevents excessive muscle growth. Isembyld reduces the amount of active myostatin in the body, resulting in more muscle growth. Isembyld is administered via IV infusion (a tube into the vein).
Learn more
Visit isembyld.com.
Spinal muscular atrophy (SMA)
Phase 3 Clinical Trial: Enrolling
This study, called SOLAR, will evaluate whether treatment with the investigational drug salanersen is safe and effective for older teens and adults with SMA.
Inclusion criteria include:
- Genetic or clinical diagnosis of SMA
- Between 15 and 60 years old
- Able to sit without using support for at least 10 seconds
Overview
In most people with SMA, the SMN1 gene is missing or changed, leading to lower SMN protein levels in the body. Without enough of this protein, motor neurons break down and muscles can’t work properly. A similar gene, called SMN2, can produce some SMN protein. Salanersen is designed to help the SMN2 gene make more SMN protein.
The SOLAR study is open-label, meaning that all participants will receive salanersen. Salanersen is administered as a once-a-year intrathecal injection (an injection into the fluid around the spinal cord in the lower back). Participants will receive five doses over the course of the study.
The study includes two groups of participants: a group that has not previously received any treatment for SMA and a group that has taken risdiplam (Evrysdi). Participants in this group should not take Evrysdi during the study.
Timeframe
5 years
Location
Norfolk, Virginia
Contact
US Biogen Clinical Trial Center, 866-633-4636, ClinicalTrials@biogen.com
Learn more
Visit ClinicalTrials.gov and enter NCT07444476 in the “Other terms” search box, or go to mytomorrows.com/trials/sma-solar/en-us.
Spinal muscular atrophy (SMA)
Phase 2 Clinical Trial: Enrolling
This trial, called SPARKLE, is studying the investigational drug adimanebart (ARGX-119) in children and teenagers with SMA. The main goals are to determine the appropriate dose and evaluate its safety and effectiveness.
Inclusion criteria include:
- Genetic diagnosis of 5q-SMA
- Between 5 and 17 years old
- Able to walk at least 50 meters without walking aids
Overview
In SMA, motor neurons (cells that transmit signals from the central nervous system to muscles) break down, causing muscle weakness and wasting. ARGX-119 is designed to activate muscle-specific kinase (MuSK), a protein that is vital for the stability of the neuromuscular junction (where nerves signal muscles).
The study begins with a 24-week randomized, double-blind, placebo-controlled period comparing the effects of ARGX-119 with a placebo (an inactive substance). After the double-blind period, participants may enter an open-label extension period of up to 100 weeks, during which all participants will receive ARGX-119. A 20-week safety follow-up period will take place after the last dose. The drug is administered via IV infusion (a tube into the vein).
Timeframe
Up to 3 years
Location
23 global sites, including 15 in the US
Learn more
Visit ClinicalTrials.gov and enter NCT07287982 in the “Other terms” search box, or go to clinicaltrials.argenx.com/sparkle.
Contact
Sabine Coppieters, MD, 857-350-4834, ClinicalTrials@argenx.com
Clinical Trial Terms to Know
Double-blind: Neither researchers nor participants know which participants are taking the drug or placebo.
Open-label: Participants know what treatment they are receiving.
Placebo-controlled: Some participants receive the treatment being tested, and some receive a placebo that looks like the real treatment but has no active ingredients.
Randomized: Participants are randomly assigned to groups taking the drug or placebo.
Next Steps and Useful Resources
- Find a list of actively recruiting clinical trials.
- Stay up to date on Quest content! Subscribe to Quest Magazine and Newsletter.
Disclaimer: No content on this site should ever be used as a substitute for direct medical advice from your doctor or other qualified clinician.


